Coronary Artery Disease Clinical Trial
— mTECH-RehabOfficial title:
Impact of a Mobile Technology Enabled Corrie Cardiac Rehabilitation Program on Functional Status and Cardiovascular Outcomes (mTECH-Rehab): A Randomized Controlled Trial
In this randomized clinical trial, the researchers are investigating whether a multi-component virtual/hybrid cardiac rehabilitation program will improve functional status, cholesterol level, overall cardiovascular health, individual risk factors, quality of life and mental health for patients who have recently been diagnosed with myocardial infarction, received a coronary stent, underwent heart surgery or catheter-based valve replacement, as compared to usual care.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 years or older - Individuals admitted to the hospital for the following conditions or interventions during the index admission: Acute myocardial infarction (STEMI or NSTEMI type 1), Coronary artery bypass grafting (CABG), and Coronary artery angioplasty/stenting (PCI), Heart valve surgery, catheter-based aortic valve replacement (TAVR). Exclusion Criteria - Non-English speaking - Symptomatic severe aortic stenosis or other severe valvular disease - Physical disability that would preclude safe and adequate exercise performance - Hypertrophic obstructive cardiomyopathy with peak resting left ventricular outflow gradient of >25 mmHg - Known aortic dissection - Severe resting arterial hypertension (Systolic blood pressure >200 mmHg or diastolic BP >110mmHg) at baseline assessment - Mental impairment leading to inability to cooperate with study procedures - Untreated high degree atrioventricular block - Atrial fibrillation with uncontrolled ventricular rate (Heart rate >110 at rest) at baseline assessment - History of cardiac arrest or sudden death - Myocardial infarction or cardiac surgery complications with cardiogenic shock and/or congestive heart failure and/or signs/symptoms of post-procedure ischemia - Left ventricular ejection fraction <40% - History of Clinically significant depression - Visual or hearing impairment which precludes the use of the intervention - Presence of cardiac defibrillator - Incomplete revascularization procedure - History of one or more episodes of falls in the last year - Pregnancy - If patients are deemed clinically unstable and unable to participate at the time of initial screening, the research team member may return at a later date to determine whether this status has changed. |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins University | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University | American Heart Association, Apple Inc. |
United States,
Isakadze N, Kim CH, Marvel FA, Ding J, MacFarlane Z, Gao Y, Spaulding EM, Stewart KJ, Nimbalkar M, Bush A, Broderick A, Gallagher J, Molello N, Commodore-Mensah Y, Michos ED, Dunn P, Hanley DF, McBee N, Martin SS, Mathews L. Rationale and Design of the mTECH-Rehab Randomized Controlled Trial: Impact of a Mobile Technology Enabled Corrie Cardiac Rehabilitation Program on Functional Status and Cardiovascular Health. J Am Heart Assoc. 2024 Jan 16;13(2):e030654. doi: 10.1161/JAHA.123.030654. Epub 2024 Jan 16. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The difference in functional status as measured by 6 minute walk test | Conducted on ground level timed for 6 minutes and measuring distance walked in meters and compared at 12 week follow up between intervention vs control arm. | 16 weeks | |
Secondary | The difference in Low Density Lipoprotein - Cholesterol (LDL -C) control as measured by the level of LDL - C | LDL cholesterol level measured (in mg/dl) at 12 week follow up visit and compared between the intervention vs control arms. | 16 weeks | |
Secondary | The difference in cardiovascular health as measured by composite cardiovascular health Composite metric for secondary prevention | The difference in the composite score of cardiovascular health metric for secondary prevention (adapted from American Heart Association's Life Simple 7) in the intervention vs control arm. The score ranges from 0 to 14 with higher score indicating better cardiovascular health. | 16 weeks | |
Secondary | The difference in cardiac rehabilitation engagement as measured by the proportion of participants attending 12 sessions of total cardiac rehabilitation attended (in person or off site) within 90 days of a cardiovascular event | Proportion of participants attending 12 sessions of total cardiac rehabilitation (in person or off site) within 90 days of a cardiovascular event in intervention arm vs control arm. | 16 weeks | |
Secondary | The difference in quality of life as measured by Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health-10 | The 10-item patient-reported questionnaire administered at 12 weeks follow up in which the response options are presented as 5-point (as well as a single 11-point) rating scales. The results of the questions are used to calculate two summary scores: a Global Physical Health Score and a Global Mental Health score. These scores are then standardized to the general population, using the "T-Score". The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient. | 16 weeks | |
Secondary | The difference in blood pressure as measured by systolic blood pressure | Measured by study staff in millimeters of mercury (mmHg) and comparing mean values between intervention and control arm. | 16 weeks | |
Secondary | The difference in blood pressure as measured by diastolic blood pressure | Measured by study staff (in mmHg) and comparing mean values between intervention and control arm. | 16 weeks | |
Secondary | The difference in adiposity as measured by waist circumference | The difference in mean waist circumference at 12 weeks follow up, measured in centimeters (cm) by study staff. | 16 weeks | |
Secondary | The difference in body weight as measured by mean body mass index | As measured by study staff. BMI = weight (kg) / height in meters squared (m^2). | 16 weeks | |
Secondary | The difference in glucose control as measured by glycosylated hemoglobin (Hb A1c) levels | Hb A1c level (percentage) measured at 12 week follow up visit and compared between the intervention vs control arms. | 16 weeks | |
Secondary | The difference in lipid profile as measured by mean total cholesterol level | Total cholesterol level measured at 12 week follow up visit and compared between the intervention vs control arms. | 16 weeks | |
Secondary | The difference in lipid profile as measured by mean High Density Lipoprotein - Cholesterol (HDL - C) level | High density lipoprotein level measured in mg/dL at 12 week follow up visit and compared between the intervention vs control arms. | 16 weeks | |
Secondary | Difference in smoking rates as measured by the proportion of current tobacco users | The difference in proportion of participants who are current tobacco users at 12 weeks per patient report. | 16 weeks | |
Secondary | The difference in diet as measured by Rate Your Plate score | A 27 item scale administered at 12 weeks with the following scoring system:
27-45: There are many ways you can make your eating habits healthier. 46-63: There are some ways you can make your eating habits healthier. 64-81: You are making many healthy choices. |
16 weeks | |
Secondary | The difference in depressive symptoms as measured by Patient Health Questionnaire 8 (PHQ 8) | The 8 item questionnaire administered at 12 weeks with the following scoring system: A score of 10 or greater is considered major depression, 20 or more is severe major depression. | 16 weeks | |
Secondary | The difference in anxiety level as measured by Generalized Anxiety Disorder 7 (GAD 7) | The 7-item questionnaire administered at 12 weeks follow up with the following scoring system. Each item is assigned scores of 0, 1, 2, and 3 to the response categories. GAD-7 total score for the seven items ranges from 0 to 21. 0-4: minimal anxiety 5-9: mild anxiety 10-14: moderate anxiety 15-21: severe anxiety | 16 weeks | |
Secondary | The difference in anxiety level as measured by Perceived Stress Scale (PSS -10) | The 10 item questionnaire administered at 12 weeks follow up. Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress. | 16 weeks | |
Secondary | The difference in patient activation as measured by Patient Activation Measure 10 (PAM 10) | The 10-item five-point Likert scale for assessing patient activation at 12 weeks follow up is used with scoring ranging from 1 to 5 and higher scores indicating the patient possesses the necessary knowledge, skills, and confidence needed for self-care. The total score reference range is from 0 to 100, where lower scores indicate lower patient activation. | 16 weeks | |
Secondary | The difference in Health Literacy as measured by The (e) Health Literacy Scale (eHEALS) | The 8 item scale administered at 12 weeks follow up. Total scores of the eHEALS range from 8 to 40, with higher scores representing higher self-perceived (e) Health literacy. | 16 weeks | |
Secondary | The difference in safety outcomes as measured by the difference in number of patients requiring hospitalization | Hospitalization as reported in electronic health records or via patient/caregiver report, verified by health records at 12 weeks follow up. | 16 weeks | |
Secondary | The difference in safety outcomes as measured by the difference in number of patients Requiring emergency room visits | Emergency room visits as reported in electronic health records or via patient/caregiver report, verified by health records at 12 weeks follow up. | 16 weeks | |
Secondary | The difference in safety outcomes as measured by the difference in number of patients with Myocardial infarction | Myocardial infarction as reported in electronic health records or via patient/caregiver report, verified by health records at 12 weeks follow up. | 16 weeks | |
Secondary | The difference in safety outcomes as measured by the difference in number of patients with stroke | Stroke as reported in electronic health records or via patient/caregiver report, verified by health records at 12 weeks follow up. | 16 weeks | |
Secondary | The difference in safety outcomes as measured by the difference in number of patients who died | Death as reported in electronic health record or via caregiver report, verified by death certificates or health records at 12 weeks follow up. | 16 weeks | |
Secondary | The difference in cognitive function as assessed by Montreal Cognitive Assessment (MoCA) | The 30 item test, administered at 12 weeks follow up. Scores on the MoCA range from 0 to 30. A score of 26 and higher is considered normal. | 16 weeks | |
Secondary | The difference in engagement in in-person cardiac rehabilitation sessions as measured by number of individuals completing in-person cardiac rehabilitation sessions | Number of individuals completing 2, 12, 24 and 36 in person cardiac rehabilitation sessions at 12 weeks follow up. | 16 weeks | |
Secondary | Cost of Care as assessed by a Markov Model of Cost-effectiveness | The hospital costs (in US dollars) for emergency department (ED) visits and hospital readmissions will be compared between Corrie Virtual Cardiac Rehabilitation Program and usual care groups at 12 weeks follow up. | 16 weeks | |
Secondary | User Engagement as assessed by total number of interactions with smartphone application | Total number of interactions in the smartphone app per participant, collected via the Corrie Health Platform User Analytics at 12 weeks follow up (only assessed in intervention arm). | 16 weeks | |
Secondary | User Engagement as assessed by overall amount of time spent using the smartphone app | Overall amount of time spent using the smartphone app per participant, collected via the Corrie Health Platform User Analytics at 12 weeks follow up (only assessed in intervention arm). | 16 weeks | |
Secondary | User Satisfaction as assessed by modified system usability scale | A 10-item five-point Likert scale for assessing systems usability of Corrie Virtual Cardiac Rehabilitation Program at 12 weeks follow up with scoring from 0 to 4 and higher scores meaning patients perceive the system as having global usability. The total score reference range is from 0 to 100, where lower scores indicate lower perceived application usability. The investigators will administer system usability scale for different features of Corrie Virtual Cardiac Rehabilitation Program. | 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |